Company Overview of Visterra, Inc.
Visterra, Inc. operates as a biotechnology company. It uses its atomic interaction network analysis to identify disease targets and design therapeutics. The company focuses on therapeutics for infectious diseases and its antibody product candidate, VIS410, a human monoclonal antibody for the prevention and treatment of seasonal and pandemic influenza. It also develops dengue antibody programs; and has a drug development program for an antibody to treat four strains of dengue virus. In addition, it focuses on research programs for infectious and non-infectious diseases; and other collaborative programs. Visterra, Inc. was formerly known as Parasol Therapeutics, Inc. and changed its name to Vi...
One Kendall Square
Cambridge, MA 02139
Founded in 2007
Key Executives for Visterra, Inc.
Chief Financial Officer and Chief Operating Officer
Compensation as of Fiscal Year 2014.
Visterra, Inc. Key Developments
Visterra, Inc. Presents at The JPMorgan 32nd Annual Healthcare Conference, Jan-16-2014 10:00 AM
Jan 10 14
Visterra, Inc. Presents at The JPMorgan 32nd Annual Healthcare Conference, Jan-16-2014 10:00 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, CA 94102, United States. Speakers: Brian J. G. Pereira, Chief Executive Officer, President and Director.
Visterra Inc. Acquires Exclusive Patent License for Monoclonal Antibodies Against Dengue Virus from Massachusetts Institute of Technology
Dec 2 13
Visterra Inc. announced that it has secured an exclusive patent license from Massachusetts Institute of Technology (MIT) to a family of early-stage monoclonal antibodies that target dengue virus. These antibodies were developed by MIT in the laboratory of Dr. Ram Sasisekharan, a founder of Visterra, using novel protein engineering approaches. Visterra will apply its proprietary network analysis technology to develop a human monoclonal antibody product candidate capable of broadly neutralizing all four dengue virus serotypes.
Visterra, Inc. Announces Management Changes
Dec 2 13
Visterra, Inc. announced that it has deepened its executive management team by appointing two industry veterans to newly created roles, David Arkowitz has joined the company as Chief Operating Officer and Chief Financial Officer, and Greg Miller will serve as Vice President of Business Development and Strategic Planning. Most recently, Mr. Arkowitz was at Mascoma Corporation, where he served as Chief Financial Officer and General Manager, Mascoma Grain Tech. Prior to joining Mascoma, he was Chief Financial Officer and Chief Business Officer of AMAG Pharmaceuticals. Most recently, Mr. Miller served as Vice President of Business and Corporate Development at Concert Pharmaceuticals since 2010. Prior to that, he was Senior Director of Business Development and Corporate Strategy at AMAG Pharmaceuticals from 2008 to 2010.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|